At High Heights Biotech, we are committed to bridging the gap between biotech innovations and business, making them accessible globally to those who need it most.
About Helio Liver
We are proud to announce that High Heights Biotech has been appointed as the official business development partner for the international launch of HelioLiver™ early detection cancer testing by Helio Genomics. With a shared commitment to improving healthcare outcomes, we are dedicated to expanding access to this ground-breaking technology and fostering collaborative partnerships to introduce HelioLiver™ to healthcare providers and patients worldwide.
A New Solution for Early Cancer Detection
The HelioLiver test delivers superior performance characteristics when compared to traditional blood tests for hepatocellular carcinoma.
HELIOLIVER 91% Specificity | AFP | GALAD | |
---|---|---|---|
Early Stage Sensitivity | 76% | 57% | 65% |
Overall Sensitivity | 85% | 62% | 75% |
Empowering Biotech Innovators
on the Global Stage
Introducing the HelioLiver™ Test
HelioLiver™ is a revolutionary multi-analyte blood test that reimagines how we find and fight liver cancer by simplifying screening for patients.
HelioLiver™ requires only a simple blood draw that offers at-risk patients an easy way to detect early liver cancer allowing for more time to treat the disease and for significantly improve outcomes.
HelioLiver™ represents a breakthrough in early detection, leveraging state-of-the-art technology to analyse circulating protein tumour markers and cell-free DNA (cfDNA) methylation testing to identify hepatocellular carcinoma (HCC) with unprecedented accuracy.
If you’re ready to take your biotech business to new heights and expand your global reach, look no further than High Heights Biotech. Contact us today to schedule a consultation and let us help you unlock the potential of international marketing in the world of medical device biotechnology. Together, we can make a difference.
Bridge the Gap between innovation and business, with
High Heights Biotech
OUR SERVICES
Tailored Go-To-Market Solutions
At High Heights Biotech, we recognize that the success of your biotechnology lies not only in its scientific breakthrough but also in its ability to reach the right audience. With our extensive network and global reach, we have the power to introduce your groundbreaking innovations to key stakeholders, investors, networks, and customers worldwide
Tailored Commercial Strategy
Our approach is rooted in meticulous market research and analysis. We dig deep to understand the unique challenges and opportunities in your industry, identify emerging trends, and uncover untapped market segments. Armed with this knowledge, we develop data-driven strategies that position your biotech innovation for maximum impact and market penetration
Tailored Business Partner Vetting
Business partner vetting is crucial for ensuring that you choose the right individuals or entities when entering into partnerships. At High Heights Biotech we conduct an in-depth assessment of your business goals, objectives, and areas where you require support or expertise, and identify potential partners with the key criteria required such as industry experience, technical skills, market knowledge, geographic reach, financial stability, and cultural fit.
Tailored On-Going Management
Once commercialised, our service doesn’t stop there. At High Heights Biotech we can provide tailored ongoing management solutions to drive sustainable growth and profitability over the long term. This may involve continuous monitoring and analysis of business performance, commercial objectives, market trends, customer preferences & feedback, opportunities & threats, competitor actions, and regulatory changes.
Contact Us
Improved Patient Outcomes
Remove barriers to routine screening with expanded availability and convenience
High Sensitivity
Our test is more sensitive than currently available blood based tests for the early detection of HCC
Reliability
Get simple, easy-to-interpret results that are immediately actionable for providers and patients
Outcomes
Remove barriers to routine screening with expanded availability and convenience